TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

uniQure Notice of Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kessler Topaz Meltzer & Check, Llp
uniQure Notice of Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations by uniQure N.V. after the FDA rejected the company's Biologics License Application for AMT-130, a gene therapy for Huntington's disease. The rejection caused uniQure's stock to plummet over 50% on November 3, 2025, from $67.69 to $34.29. The firm is encouraging investors with significant losses to contact them.

Insights
QURE   negative

FDA rejected the company's BLA submission for its lead drug candidate AMT-130, resulting in a 50%+ stock price decline and triggering a securities investigation for potential violations of federal securities laws.